Bonnie Segal is the Co-Founder and President of Segal Trials, a 23 year old network of 8 private research sites in South Florida specializing in Phase I-IV Psychiatry, Addiction, Women’s Health and General Medicine. In 2018, Bonnie and her team expanded into psychedelics for mental health treatment and became one of the first private sites in the US to conduct psychedelic research. Since then Segal Trials established its Center for Psychedelic and Cannabis Research to meet the demands of the evolving psychedelic industry. Bonnie grew a team possessing specialized regulatory experience to obtain and manage a DEA Schedule 1 license, expertise in the design and construction of custom session/dosing rooms in adherence with current FDA guidance​, unique recruitment techniques and specialized trained facilitators augmented by well-established team of over 125 research professionals. Bonnie has been a crucial part of the success of the 1,500 clinical trials conducted by the Segal Trials investigators.